149 related articles for article (PubMed ID: 38205189)
1. Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for children.
Petro E; Perumal-Pillay V; Mantel-Teeuwisse AK; van den Ham HA; Suleman F
J Pharm Policy Pract; 2024; 17(1):2290100. PubMed ID: 38205189
[TBL] [Abstract][Full Text] [Related]
2. Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa.
Joosse IR; van den Ham HA; Mantel-Teeuwisse AK; Suleman F
BMJ Glob Health; 2023 Sep; 8(9):. PubMed ID: 37730243
[TBL] [Abstract][Full Text] [Related]
3. Essential medicines for children in Armenia.
Kazaryan I; Vardanyan L
Int J Risk Saf Med; 2015; 27 Suppl 1():S43-4. PubMed ID: 26639704
[TBL] [Abstract][Full Text] [Related]
4. Essential medicines lists for children of WHO, India, South Africa, and EML of China: A comparative study.
Liu D; Cheng J; Zhang LL; Li YP; Zeng LN; Zhang C; Gui G
J Evid Based Med; 2017 Nov; 10(4):271-280. PubMed ID: 28276634
[TBL] [Abstract][Full Text] [Related]
5. Indian Essential Medicine List for Children: Time to Revisit.
Singhal S; Dutta S; Thakker Z; Shah R
Cureus; 2023 Feb; 15(2):e35340. PubMed ID: 36974248
[TBL] [Abstract][Full Text] [Related]
6. Using the WHO essential medicines list to assess the appropriateness of insurance coverage decisions: a case study of the Croatian national medicine reimbursement list.
Jeličić Kadić A; Žanić M; Škaričić N; Marušić A
PLoS One; 2014; 9(10):e111474. PubMed ID: 25337860
[TBL] [Abstract][Full Text] [Related]
7. Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011-2021.
Bai L; Zhan Y; Zhou Y; Zhang Y; Shi L; Gupta S; Denburg A; Guan X
EClinicalMedicine; 2023 May; 59():101966. PubMed ID: 37125406
[TBL] [Abstract][Full Text] [Related]
8. Quantitative evaluation of essential medicines lists: the South African case study.
Perumal-Pillay VA; Suleman F
BMC Health Serv Res; 2016 Dec; 16(1):687. PubMed ID: 27955710
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Appropriateness of Formulations on the WHO Model List of Essential Medicines for Children: Development of a Paediatric Quality Target Product Profile Tool.
Walsh J; Masini T; Huttner BD; Moja L; Penazzato M; Cappello B
Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335850
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of marketing authorization and labels of medicines in 2021 WHO Model List of Essential Medicines for Children in China, the Russian Federation and Brazil.
Li C; Cheng L; Zhang X; Zhang L; Yan J
Health Res Policy Syst; 2024 Mar; 22(1):33. PubMed ID: 38443935
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region.
Mehrtash H; Laing R; Wirtz VJ
East Mediterr Health J; 2018 Jul; 24(5):427-434. PubMed ID: 30043961
[TBL] [Abstract][Full Text] [Related]
13. Analysis of evidence supporting the Federation of Bosnia and Herzegovina reimbursement medicines lists: role of the WHO Essential Medicines List, Cochrane systematic reviews and technology assessment reports.
Mahmić-Kaknjo M; Marušić A
Eur J Clin Pharmacol; 2015 Jul; 71(7):825-33. PubMed ID: 25956715
[TBL] [Abstract][Full Text] [Related]
14. Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study.
Ivanovska V; Leufkens HG; Rademaker CM; Zisovska E; Pijnenburg MW; van Dijk L; Mantel-Teeuwisse AK
Arch Dis Child; 2017 Apr; 102(4):352-356. PubMed ID: 28119403
[TBL] [Abstract][Full Text] [Related]
15. Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study.
Shimazawa R; Ikeda M
J Pharm Policy Pract; 2017; 10():4. PubMed ID: 28070339
[TBL] [Abstract][Full Text] [Related]
16. A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list.
Naicker I; Suleman F; Perumal-Pillay VA
J Pharm Policy Pract; 2022 Dec; 15(1):97. PubMed ID: 36482421
[TBL] [Abstract][Full Text] [Related]
17. Medicines for cancers in children: The WHO model for selection of essential medicines.
Robertson J; Magrini N; Barr R; Forte G; Ondari C
Pediatr Blood Cancer; 2015 Oct; 62(10):1689-93. PubMed ID: 25929524
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study.
Adekoya I; Maraj D; Steiner L; Yaphe H; Moja L; Magrini N; Cooke G; Loeb M; Persaud N
Lancet Infect Dis; 2021 Oct; 21(10):1429-1440. PubMed ID: 34332706
[TBL] [Abstract][Full Text] [Related]
19. Withdrawn medicines included in the essential medicines lists of 136 countries.
Charles O; Onakpoya I; Benipal S; Woods H; Bali A; Aronson JK; Heneghan C; Persaud N
PLoS One; 2019; 14(12):e0225429. PubMed ID: 31791048
[TBL] [Abstract][Full Text] [Related]
20. Access to WHO Essential Medicines for Childhood Cancer Care in Trinidad and Tobago: A Health System Analysis of Barriers and Enablers.
Tang B; Bodkyn C; Gupta S; Denburg A
JCO Glob Oncol; 2020 Feb; 6():67-79. PubMed ID: 32031441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
